When reviewing and updating my due dilligence its was overwealming how much this management team has accomplished and only diluting 2 million shares in 2020. Phase 1 had been a success in March and to fast forward 9 months to having Phase II in 3 countries with government funding is such an achievement. The longer this trial lasts and the more Hospitals that sign up for it, ultimately increases my bullishness on this technology and the impact it will have on the market. The Market cap has decreased since my last update with tremendous material change occuring since including a non diluted 6.7 million dollars. 2021 will reward us longs, the momentum is in our favour and todays NR gave me more confidence.
"Today, I can announce that we are providing up to $6.7 million for the Canadian company Arch Biopartners, to support the development of their leading drug candidate to treat severe COVID-19 cases.This new funding was provided on the advice of Canada’s leading experts in the field who are serving on our COVID-19 Therapeutics Task Force."
JUSTIN TRUDEAU
First thing you should do is look at insider ownership: Arch - 54% - TD WATERHOUSE INSIDER
Second, are there warrants outstanding? Arch - Zero Warrants outstanding - MD&A - Aug 31, 2020
https://www.sedar.com/FindCompanyDocuments.do Insider Buying? PAST 12 Months! CEO - 84,000 shares - March 24,2020
- 420,000 Options excersiced - Jan 24, 2020
https://www.canadianinsider.com/node/7?menu_tickersearch=ARCH+%7C+Arch+Biopartners They must have done a huge raise when they went from .36 - $1.80 though... right? WRONG: January 29, 2018 - 55,229,679 common shares issued and outstanding
March 2, 2020 - 59,882,302 common shares issued and outstanding
January 5, 2021 - 61,212,302
common shares issued and outstanding https://www.sedar.com/FindCompanyDocuments.do Does Arch have Patents for their science? Metablock / LSALT - Multiple Patents - Drug Library - Commercial rights
https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/2999800/summary.html?query=arch+biopartners&type=basic_search
https://www.archbiopartners.com/index.php/investor-hub/fundamentals/press-releases-live/154-arch-biopartners-discloses-new-patent-filing-for-novel-drug-candidates-to-prevent-lung-inflammation https://www.archbiopartners.com/index.php/investor-hub/fundamentals/press-releases-live/32-press-releases-2019/144-arch-biopartners-announces-issuance-of-us-patent-for-dipeptidase-1-inhibitor-drug-for-use-in-acute-kidney-injury Arch is developing a pipeline of new drug candidates that inhibit inflammation in the lungs, liver and kidneys via the dipeptidase-1 (DPEP-1) pathway for multiple medical indications. ( I believe 4 Mentioned in Webinar) AB569 - Drug Patent - Commercial rights (Oddly enough, I got in for this drug)
https://www.archbiopartners.com/index.php/investor-hub/fundamentals/press-releases-live/31-press-releases-2018/119-arch-biopartners-announces-issuance-of-us-patent-for-its-novel-antibacterial-drug-ab569-designed-to-target-chronic-infection-and-antibiotic-resistance Have they recieved Gov Grants Before? TO BUILD A DRUG LIBRARY!!! https://www.archbiopartners.com/index.php/investor-hub/fundamentals/press-releases-live/32-press-releases-2019/132-arch-biopartners-awarded-nrc-irap-funding-to-further-develop-metablok-drug-program The only therapeutic funded by the Government of CANADA https://www.canada.ca/en/innovation-science-economic-development/news/2020/12/government-of-canada-invests-in-promising-treatment-that-could-fight-covid-19.html#shr-pg0 Do these drugs work though? Publications and Videos of science working in animals: Metablok -
https://www.cell.com/action/showPdf?pii=S0092-8674%2819%2930782-2 -
https://www.archbiopartners.com/index.php/our-science/our-key-platforms/metablok AB569 -
https://www.globenewswire.com/NewsRoom/AttachmentNg/9328b8b7-9f45-4361-915c-3a569b3716a0 https://www.liebertpub.com/doi/10.1089/dna.2020.5824 Company Metablok / LSALT Webinar -
https://zoom.us/rec/play/E3gBfzmmLQxW7REF-lo_sCBgfFTUYNb4RVEJ07Bqn1YON9BYH6iMrfY-pRhC-gI8vHGUke9CDgo9N1yJ.Xw6L63LsOdGdNOqz?startTime=1597762652000&_x_zm_rtaid=QM8d4WVVQZmMF1e0M9fkNQ.1602875790298.1b21cd13b51261456df8fa4dbba328a1&_x_zm_rhtaid=746 Why is Phase 2 important? Metablok has potential to work in the LUNG, KIDNEY AND LIVER, Management knows this and the Phase 2 will now test LUNG and KIDNEY. This massively reduces the risk and greatly increases the reward IMHO. The Kidney alone has no competition and a treatment market of 1,000,000 a year. Industry compareables for a 14 day treatment run $3,000-5,000. This is 3-5 billion revenue a year market WITH NO COMPETITION. Arch Market cap 88.8 million.... Survival rates and health care system capacity could both be improved with new treatments that prevent the severe manifestations of COVID-19, such as worsening lung inflammation (ARDS) and AKI experienced by patients infected with SARS-CoV-2.2
1 Hirsch JS et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 2020
doi: https://doi.org/10.1016/j.kint.2020.05.006.
2 J. S. Ayres, Sci. Adv 10.1126/sciadv.abc1518 (2020)
The primary endpoint is to prevent the development of life threatening acute respiratory distress syndrome (ARDS) in patients early in the course of COVID-19.
A secondary endpoint of the Phase II trial is to
prevent kidney inflammation and injury, which also contributes to mortality and occurs in
up to 35% of patients (An increase from 30%) with severe COVID-19.
OK, Who is the ARCH chief Scientist? (He might just know about the kidney)
Dr. Daniel Muruve
Chief Science Officer and Co-Founder
Daniel Muruve is a Professor in the Department of Medicine at the University of Calgary. He graduated from the Faculty of Medicine at the University of Manitoba in 1989 and has undertaken extensive post-graduate medical and scientific training over 10 years at the University of Calgary, Harvard University and the University of Lausanne. Dr. Muruve is a certified kidney specialist and a basic scientist with expertise in the biology of kidney disease and the molecular basis of inflammation and the immune system. He is an AHFMR Clinical Senior Scholar and
holds a Canada Research Chair in Inflammation and Kidney Disease. But who is on the Arch Board and Advisors?
Adrian Haigh
Director
Adrian Haigh was recently Senior Vice President, Commercial Operations and Chief Operating Officer of Gentium GmbH,
playing a pivotal role in the sale of Gentium to Jazz Pharma for $1 billion in December 2013. Prior to joining Gentium, Mr. Haigh served as Regional Vice President, Commercial Operations at Biogen Idec where he managed the global distributor business. From 2002 to 2007 he held leadership positions at Amgen, incl. General Manager of Portugal and Scandinavia and Head of the $1.5b International Oncology Franchise. His career also includes management positions with SmithKline Beecham, Schering-Plough, Organon and Novo-Nordisk.
Patrick Vink
Strategic Advisor
Dr. Vink is a well-known and active member of the European and North American life sciences community. In 2012, Dr. Vink joined Cubist Pharmaceuticals, a company focused on developing new antibiotics to treat drug-resistant bacterial infections. At Cubist, he served as Executive Vice President and Chief Operating Officer until the company was
bought by Merck for a total transaction value of $9.5 billion in 2015. Previously, he has held several leadership positions across the pharmaceutical industry, including Senior Vice President, Global head of Hospital Business and Biologics of Mylan Inc. (2008-2012), Head of Global Business Franchise Biopharmaceuticals at Novartis Sandoz (2002-2006), Vice President of International Business at Biogen (2000-2002) and Head of Worldwide Marketing, Cardiovascular and Thrombosis at Sanofi (1997-2000). Dr. Vink also was a member of the executive committee of the European Federation of Pharmaceutical Industries and Associations between 2013 and 2015. He is currently active as an advisor to the Life Sciences sector, serving as Chairman of Targovax in Oslo, Norway (immuno-oncology) and Santhera in Basel, Switzerland (rare diseases) and also on the board of directors of Acacia Pharma and Spero Therapeutics.
CEO, Director, Co-founder
Mr. Muruve co-founded Arch Biotech Inc. with the Arch Inflammation team in 2006. Arch Biotech operated as a private company for four years and motivated the formation of Arch Biopartners in 2010. At that time, Arch Biopartners simultaneously acquired the commercial rights to the brain tumour targeting and peptide-solid surface technology platforms, launching the portfolio approach to drug development that Arch continues to oversee today. Prior to Arch Biotech, Mr. Muruve was a
Vice President at Bank of Montreal where he spent 12 years in the Investment Banking Group. Mr. Muruve has a MBA from the University of British Columbia.